登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H33NO2
化学文摘社编号:
分子量:
391.55
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
SMILES string
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChI key
UVIQSJCZCSLXRZ-UBUQANBQSA-N
grade
pharmaceutical primary standard
API family
abiraterone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... CYP17A1(1586)
正在寻找类似产品? 访问 产品对比指南
General description
Abiraterone acetate is a pro-drug of abiraterone and a potent inhibitor of the enzyme CYP17, required for androgen biosynthesis in the adrenal glands, testes and prostate tissue.
Application
Abiraterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Abiraterone Acetate Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
target_organs
Endocrine system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Ryan.JC, et al.
Clinical Cancer Research, 14(7), 4854-4861 (2011)
Ryan.JC, et al.
Journal of Clinical Oncology, 28(9), 1481-1488 (2010)
Abiraterone Acetate Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 26-26 (2022)
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Danila.CD, et al.
Journal of Clinical Oncology, 28(9), 1496- 1501 (2010)
Abiraterone Acetate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 25-25 (2020)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持